- Report
- February 2025
- 200 Pages
Global
From €3921EUR$4,490USD£3,406GBP
- Report
- September 2025
- 489 Pages
Global
From €5109EUR$5,850USD£4,438GBP
- Report
- August 2025
- 184 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 184 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 196 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- August 2025
- 182 Pages
Global
From €3096EUR$3,545USD£2,690GBP
€3440EUR$3,939USD£2,988GBP
- Report
- September 2021
- 201 Pages
Global
From €4191EUR$4,799USD£3,641GBP
- Report
- July 2024
- 150 Pages
Global
From €3275EUR$3,750USD£2,845GBP
- Report
- November 2020
- 199 Pages
Global
€3930EUR$4,500USD£3,414GBP
- Report
- August 2023
- 116 Pages
Global
From €3500EUR$4,293USD£3,147GBP
- Book
- February 2012
- 216 Pages
The Ocular Drug Delivery market is a subset of Transdermal and Transmucosal Drug Delivery, which refers to the administration of drugs through the skin or mucous membranes. Ocular Drug Delivery is the delivery of drugs to the eye, either through topical application or through systemic administration. This method of drug delivery is used to treat a variety of ocular diseases, including glaucoma, dry eye, and age-related macular degeneration. Ocular Drug Delivery is advantageous because it allows for the targeted delivery of drugs to the eye, reducing the risk of systemic side effects.
The Ocular Drug Delivery market is highly competitive, with a variety of companies offering products and services. Some of the major players in the market include Allergan, Bausch + Lomb, Santen Pharmaceuticals, Novartis, and Alcon. Show Less Read more
